Pharmaniaga posted a net profit of RM12.49 million for the second quarter ended June 30, 2026, more than triple the RM3.96 million reported in the same period last year [1, 2, 3, 4]. The company's revenue for Q2 rose 12% to RM1.04 billion from RM926.86 million a year earlier, supported by increased orders from government hospitals and higher private sector sales [1, 2, 3, 4].
The company attributed part of its profit growth to approximately RM7 million saved on interest expenses, following partial repayment of borrowings in the quarter [1, 2, 3]. For the first half of 2026, Pharmaniaga's net profit climbed 31% to RM43.96 million from RM33.54 million, while revenue increased nearly 12% to RM2.22 billion from RM1.98 billion [1, 2, 3, 4].
Pharmaniaga secured a RM281.7 million contract to supply human insulin over three years, expected to begin contributing in the second half of 2026 [1, 2, 3]. The company is advancing the commercialisation of its biopharmaceutical portfolio while continuing to bolster its pharmaceutical and logistics operations and expanding in regional markets [1, 2, 3].
Significant progress was also made in Pharmaniaga’s vaccine localisation programme, including completing PCV-13 process validation batches and obtaining Good Manufacturing Practice certification from the National Pharmaceutical Regulatory Agency [1].
The company declared a second interim dividend of 0.48 sen per share, with an ex-dividend date set for September 14, 2026, and payment scheduled for October 13, 2026 [1, 2, 3, 4]. On August 13, 2026, Pharmaniaga’s share price closed at RM1.17, down 1 sen, valuing the company at about RM1.53 billion [1, 2].
Datuk Zulkifli Jafar, Pharmaniaga’s managing director, said, "Looking ahead, we remain encouraged by the steady progress of our pharmaceutical and biopharmaceutical initiatives, particularly the localisation of strategic healthcare products that will strengthen Malaysia's supply security while supporting long-term margin enhancement" [1].
